Sunday, 16 June 2019

Most Popular
Pharma News
BioTech News
MedTech News
BioServices News
Video Gallery

Inside Magazine


Healthcare private equity tends to be less vulnerable to downturns than other sectors, so it expects demand for assets in Asia-Pacific to increase over the coming years. Buyout funds will invest more in growth-stage assets such as Chinese pharma. And as companies explore ways to increase access to healthcare, emerging trends, such as digital healthcare solutions, should gain steam in China, India and other countries. Investors will continue to seek deals in the provider and medtech sectors, and explore creative ways to deploy capital, such as public-toprivate takeovers. Baker McKenzie Global Transactions Forecast predicts a modest rise of 7 per cent in deals to $331 billion in 2019, as a number of cross-border and domestic megadeals are set to close.

Sign up here to access BioSpectrum Asia flip book.